TrialBreast cancer research and treatment2025

Randomized phase II comparison of single-agent carboplatin versus combination of carboplatin and everolimus for advanced triple negative breast cancer.

Rima Patel et al.PubMed ↗Publisher ↗

No numbers read from the abstract.